Clinical Trials
125 trialsTT4B
University of Arkansas
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
University of Arkansas
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
University of Arkansas
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
University of Arkansas
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Cassiopeia
Intergroupe Francophone du Myelome
VCAT
Janssen Scientific Affairs, LLC
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
University of Turin, Italy
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
Arbeitsgemeinschaft medikamentoese Tumortherapie
Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
UniversitƤtsklinikum Hamburg-Eppendorf
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
Canadian Cancer Trials Group
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Selinexor in Combination With Immunomodulator ļ¼Thalidomide/Pomalidomide/Lenalidomideļ¼in RRMM
Shanghai Changzheng Hospital
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
Roswell Park Cancer Institute
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
OPTIMAL
Oxford University Hospitals NHS Trust
BMT CTN 0102
National Heart, Lung, and Blood Institute (NHLBI)
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
European Society for Blood and Marrow Transplantation
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
City of Hope Medical Center
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
T-BiRD
Weill Medical College of Cornell University
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Sichuan University
CATALYST
University College, London
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
Guangdong Provincial People's Hospital
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Canadian Cancer Trials Group
IDEALL
Takeda
Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Arbeitsgemeinschaft medikamentoese Tumortherapie
FIRST
Celgene
OPTIMUM
Celgene
Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
Celgene
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Maryland, Baltimore
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
M.D. Anderson Cancer Center
Thalidomide-Dexamethasone for Multiple Myeloma
M.D. Anderson Cancer Center
Thalidomide for Multiple Myeloma
M.D. Anderson Cancer Center
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
SWOG Cancer Research Network
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
SWOG Cancer Research Network
Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients
Gruppo Italiano per lo Studio del Mieloma Multiplo
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM
Azienda Ospedaliera di Bolzano
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
University of Leeds
Myeloma XI
University of Leeds
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
National University Hospital, Singapore
DexTR
Weill Medical College of Cornell University
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins